ExpressPoints: The New Biomarkers Pathologists Need to Know for Precision Therapy in Lung Cancer

Safety and response data from phase Ib TROPION-Lung02 study of Dato-DXd plus pembrolizumab with or without platinum chemotherapy in advanced NSCLC, presented at WCLC 2022 reported by Clinical Care Options (CCO)

Results from the HUDSON umbrella trial of novel durvalumab combination regimens in patients with advanced NSCLC who failed previous immunotherapy treatment, presented at WCLC 2022 and reported by Clinical Care Options (CCO)

Initial PFS and OS results from phase II NADIM II study of neoadjuvant nivolumab plus CT vs CT alone in patients with resectable stage IIIA-B NSCLC, presented at WCLC 2022 and reported by Clinical Care Options (CCO)

Evaluation of YESS study adding personalized smoking cessation support to a lung cancer screening program, presented at WCLC 2022 and reported by Clinical Care Options (CCO)